Oncology Business Management

Progenics Pharmaceuticals, Inc. is trimming its staff by 26% and cutting its infectious disease and virology programs so that it can focus solely on its oncology program.

Dr. Adam Brufsky from the University of Pittsburgh School of Medicine Advises Doctors on Bevacizumab (Avastin) for Breast Cancer

Dr. Teresa Woodruff from Feinberg School of Medicine, Northwestern University, Discusses Oncofertility Insurance Coverage

It’s no surprise that you acquire significant debt during your medical training. Here are some ways to get those loans paid off.

Burnout is a recurring problem for overworked oncologists and hematologists. This article includes ideas to keep you healthy, engaged, and empathic.

Obtaining a high-quality bone marrow aspirate and biopsy is very important for the patient—and for you. Following these general guidelines will help you do this successfully.

All fellows will at some point in their careers be required to speak in public. This article provides a number of tips to make that task easier.

As millions of Americans grapple with changes in Medicare and other health insurance coverage, thousands of oncologists could find their medical practices threatened by insolvency.

Here are a few incontrovertible facts: our population is growing and aging; people are living longer; and care is more complex and applied for longer periods, so it is more costly.

Dr. Corey Langer from Abramson Cancer Center on Cost Analysis in the Treatment Decision

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

A Letter from Andre Goy, MD, MS, about the New Frontiers in the Management of Solid and Liquid Tumors in November.

British investigators are reporting that taller women have a higher risk of cancer, and that the link between height and cancer risk exists for most types of cancer.

The Joint Commission has released this year's list of top-performing hospitals.

The first few years after medical school can seem financially suffocating for young physicians.

With the right game plan, you can open your own lucrative practice in an area previously thought to be unprofitable.

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

It seems that every year, the list of Accreditation Council for Graduate Medical Education (ACGME) requirements grows longer and more bewildering.

Researchers and clinicians are not necessarily expected to be world-class writers, but a well-written article that effectively communicates the topic at hand and adheres to the journal's standards is more likely to be published.

The healthcare system in the United States has become increasingly unsustainable.

Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker

On Friday, August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non–small cell lung cancer (NSCLC).

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67

Dr. Jack West from the Swedish Cancer Institute Talks About the Escalating Cost of Cancer Care